ST. PAUL – Achieving high product purity early in the manufacturing process and improving efficiency is important to biopharmaceutical manufacturers and increasing removal of impurities such as DNA and HCP during clarification improves the performance of downstream capture and polishing steps.
Already have an account? Log In




